Supplement to Prospectus regarding invitation to subscribe for units in Alligator Bioscience AB (publ)

24 May 2023

Distribution of this supplementary prospectus is restricted in certain jurisdictions, see further in the section “Important information” in the Prospectus.

SUPPLEMENT TO THE PROSPECTUS

This document (the "**Supplement Prospectus 3**") has been prepared by Alligator Bioscience AB, corporate registration number 556597-8201 ("**Alligator**" or the "**Company**"), and constitutes a supplement to the Prospectus regarding the invitation to subscribe for units in Alligator (the "**Rights Issue**") as approved and registered by the Swedish Financial Supervisory Authority on 26 April 2023 (Swedish Financial Supervisory Authority reference number 23-2847) (the "**Prospectus**") and the supplement prospectuses that were approved and registered by the Swedish Financial Supervisory Authority on 9 May 2023 (Swedish Financial Supervisory Authority reference number 23-13859) (the "**Supplement Prospectus 1**") as well as on 12 May 2023 (Swedish Financial Supervisory Authority reference number 23-14524) (the "**Supplement Prospectus 2**"). This Supplement Prospectus 3 is to be considered a part of, and shall be read in connection with, the Prospectus, the Supplement Prospectus 1, and the Supplement Prospectus 2. The definitions set forth in the Prospectus shall have the same meaning for this Supplement Prospectus 3. The Prospectus and this Supplement Prospectus 3 have been prepared in a Swedish and an English language version, respectively. In the event of any inconsistencies between the language versions, the Swedish language version shall prevail.

This Supplement Prospectus 3 has been prepared as Alligator on 18 May 2023 through a press release announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the Company's drug candidate mitazalimab for the treatment of pancreatic cancer, which is a key milestone for the continued development of the drug candidate and confers significant benefits in the form of marketing exclusivity and cost savings during development following approval.

This Supplement Prospectus 3 has been prepared in accordance with Article 23 of the Regulation (EU) 2017/1129 of the European Parliament and of the Council (the "**Prospectus Regulation**") and was approved by the Swedish Financial Supervisory Authority on 24 May 2023 (Swedish Financial Supervisory Authority reference number 23-15356). This Supplement Prospectus 3 was published by the Company on the same day.

The Prospectus, the Supplement Prospectus 1, the Supplement Prospectus 2 and this Supplement Prospectus 3 (together the "**Prospectuses**") are made available on the Company's, Aktieinvest FK AB's and Redeye AB's respective websites (www.alligatorbioscience.com, www.aktieinvest.se and www.redeye.se). The Prospectuses will also be available on the Swedish Financial Supervisory Authority's website (www.fi.se). For complete terms and conditions and other information regarding the Rights Issue, please refer to the Prospectuses.

SUPPLEMENT TO SECTION "SUMMARY"

Under section "*Key information on the Rights Issue – Why is this Prospectus being produced?*" on page 9 of the Prospectus, changes shall be made in accordance with the italic text below before the last sentence in the first paragraph under the sub-section "*Reasons for the Offering and use of the proceeds*":

Alligator has demonstrated convincing Proof of Mechanism data in Phase 1 studies for mitazalimab, its most advanced immuno-oncology drug candidate. The Company has initiated the clinical Phase 2 study OPTIMIZE-1, enrolling the first patient in September 2021. In January 2023, Alligator published the first interim data from OPTIMIZE-1, showing that approximately 52 per cent of the patients responded to the combination of mitazalimab and chemotherapy after 17 weeks of treatment. In comparison, approximately 32 per cent respond to chemotherapy alone. Moreover, the so-called disease control rate at this point was above 90 per cent. In April 2023, the Company announced that all patients have been recruited for OPTIMIZE-1, and that top line data from the study is expected in the beginning of Q1 2024. *The Company also announced in May 2023 that mitazalimab had obtained Orphan Drug Designation by the FDA, which is a key milestone for the continued development of the drug candidate.* Based on this encouraging data, the Company plans to engage US and European regulatory authorities during 2023 in order to discuss opportunities to accelerate the development of mitazalimab in pancreatic cancer.

SUPPLEMENT TO SECTION "BACKGROUND AND REASONS"

Under section "*Background and reasons*" on page 25 in the Prospectus, changes shall be made in accordance with the italic text below before the last sentence in the fifth paragraph:

In January 2023, Alligator announced the first interim data from OPTIMIZE-1, showing that approximately 52 per cent of the patients responded to the combination of mitazalimab and chemotherapy after 17 weeks of treatment. In comparison, approximately 32 per cent respond to chemotherapy alone.[1] Moreover, the so-called disease control rate at this point was above 90 per cent. In April 2023, the Company announced that all patients have been recruited for OPTIMIZE-1, and that top line data from the study is expected in the beginning of Q1 2024. *The Company also announced in May 2023 that mitazalimab had obtained Orphan Drug Designation by the FDA, which is a key milestone for the continued development of the drug candidate.* Based on this encouraging data, the Company plans to engage US and European regulatory authorities during 2023 in order to discuss opportunities to accelerate the development of mitazalimab in pancreatic cancer.

SUPPLEMENT TO SECTION "BUSINESS DESCRIPTION"

Under section "*History*" on page 39 in the Prospectus, changes shall be made in accordance with the italic text below to the last bullet point regarding events during 2023:

- 2023 – Publication of positive interim data from the mitazalimab Phase 2 study in pancreatic cancer patients. Orion Corporation exercised the option to start a second project under the 2021 collaboration and license agreement. In February 2023, the first patient was dosed in the ALG.APV-527 Phase 1 study. In April 2023, FDA cleared the Company's IND application for a Phase 2 study of mitazalimab in bladder cancer. Also in April 2023, Alligator announced that the OPTIMIZE-1 study had been fully recruited. In May 2023 Alligator announced that Orion Corporation has selected bispecific lead antibodies and is exercising its option to continue to develop these molecules under the existing research collaboration and license agreement between the two companies. *The Company also announced in May 2023 that mitazalimab had obtained Orphan Drug Designation by the FDA for the treatment of pancreatic cancer.*

Under section "*The clinical project portfolio in brief – Mitazalimab*" on page 45 in the Prospectus, changes shall be made in accordance with the italic text below after the last sentence:

Mitazalimab is an immunostimulatory CD40 antibody for the treatment of metastatic cancer, such as pancreatic cancer. Activation of the CD40 receptor on the immune system's dendritic cells enhances their ability to attack the cancer cells. Encouraging interim data from the ongoing Phase 2 trial in pancreatic cancer was published in January 2023. The OPTIMIZE-1 study is fully recruited, interim data is expected mid-2023 and full top line data from the trial is expected Q1 2024. *The Company also announced in May 2023 that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to mitazalimab.*

Under section "*Mitazalimab – Project status: Encouraging interim Phase 2 data in pancreatic cancer*" on page 47 in the Prospectus, changes shall be made in accordance with the italic text below after the last sentence in the second paragraph:

Based on *this* encouraging data, Alligator plans to initiate dialogue with European and US regulatory authorities during 2023 to explore opportunities to accelerate the development and regulatory process for mitazalimab in pancreatic cancer. In parallel, the Company has initiated the process to apply for Orphan Drug Designation and other incentivizing regulatory instruments with the US FDA and European EMA. *The Company announced in May 2023 that the FDA has granted Orphan Drug Designation to mitazalimab.*

SUPPLEMENT TO SECTION "CAPITALIZATION, INDEBTEDNESS AND OTHER FINANCIAL INFORMATION"

Under section "*Significant events after 31 March 2023*" on page 60 in the Prospectus, a new third paragraph (in addition to the second paragraph added through the Supplement Prospectus 2) shall be added in accordance with the following:

In May 2023 Alligator further announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the Company's drug candidate mitazalimab for the treatment of pancreatic cancer, which is a key milestone for the continued development of the drug candidate and confers significant benefits in the form of marketing exclusivity and cost savings during development following approval.

SUPPLEMENT TO SECTION "LEGAL CONSIDERATIONS AND SUPPLEMENTARY INFORMATION"

Under subsection "*Operational developments*" of section "*Statutory disclosures*" on page 81 of the Prospectus, a new final bullet point shall be added with the following text:

- On 18 May 2023 Alligator announces that the FDA has granted Orphan Drug Designation to the Company's drug candidate mitazalimab for the treatment of pancreatic cancer, which is a key milestone for the continued development of the drug candidate and confers significant benefits in the form of marketing exclusivity and cost savings during development following approval.